A 74-Year-Old Man With Relapsed/Refractory Follicular Lymphoma - Episode 4
Kami Maddocks, MD, highlights what findings may trigger a change in therapy or the introduction of a new agent into a patient’s current treatment.
Kami Maddocks, MD: When I treat a patient for follicular lymphoma [FL], if they achieve a complete remission to their initial therapy such as this patient did, I usually follow them every 3 to 4 months. I see them in the clinic, take a good history, do a good physical exam, and then check their labs, CVC [central venous catheter], chemistry panel, LDH [lactate dehydrogenase] for any indications of disease progression. I typically check CT [computed tomography] scans every 6 months for those first 2 years, so monitoring them in the high-risk period. After patients reach that 2 years of follow up standpoint, I usually extend their visits out to 6 months and see them every 6 months through year 5 and then go to yearly. I do CT scans from year 2 to year 5, and sometimes I will do them at most once each year to just get an idea if there’s been any progression.
Otherwise, I just use CT scans if patients call in with symptoms if I detect new lymphadenopathy on exam or if something in their lab is concerning to me. I do not do a routine PET [positron emission tomography] scan for monitoring in FL. I do like to get a PET for their end of therapy, to ensure that they’re negative by PET scan.
Transcript edited for clarity.
Case: A 74-Year-Old Man With Relapsed/Refractory Follicular Lymphoma